323 related articles for article (PubMed ID: 20519901)
21. Clinical effects of use polymyxin B fixed on fibers in liver transplant patients with severe sepsis or septic shock.
Ruberto F; Pugliese F; D'Alio A; Martelli S; Bruno K; Marcellino V; Perrella S; Cappannoli A; Mazzarino V; Tosi A; Novelli G; Rossi M; Ginanni Corradini S; Ferretti G; Berloco PB; Pietropaoli P
Transplant Proc; 2007; 39(6):1953-5. PubMed ID: 17692664
[TBL] [Abstract][Full Text] [Related]
22. New trends in polymyxin B hemoperfusion: from 2006 to 2013.
Cruz DN
Blood Purif; 2014; 37 Suppl 1():9-13. PubMed ID: 24457489
[TBL] [Abstract][Full Text] [Related]
23. Application of polymyxin B convalently immobilized fiber in patients with septic shock.
Suzuki H; Shoji H
Contrib Nephrol; 2010; 166():150-157. PubMed ID: 20473003
[TBL] [Abstract][Full Text] [Related]
24. Polymyxin B-immobilized fiber column hemoperfusion removes endotoxin throughout a 24-hour treatment period.
Mitaka C; Fujiwara N; Yamamoto M; Toyofuku T; Haraguchi G; Tomita M
J Crit Care; 2014 Oct; 29(5):728-32. PubMed ID: 24798345
[TBL] [Abstract][Full Text] [Related]
25. Extracorporeal removal of endotoxin: the polymyxin B-immobilized fiber cartridge.
Tani T; Shoji H; Guadagni G; Perego A
Contrib Nephrol; 2010; 167():35-44. PubMed ID: 20519897
[TBL] [Abstract][Full Text] [Related]
26. Endotoxin removal by polymyxin B immobilized cartridge inactivates circulating proapoptotic factors.
Martin EL; Ranieri VM
Contrib Nephrol; 2010; 167():65-76. PubMed ID: 20519900
[TBL] [Abstract][Full Text] [Related]
27. Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients.
Yamashita C; Moriyama K; Hasegawa D; Hara Y; Kuriyama N; Nakamura T; Shibata J; Komura H; Nishida O
Contrib Nephrol; 2018; 196():215-222. PubMed ID: 30041230
[TBL] [Abstract][Full Text] [Related]
28. Polymyxin B-immobilized fiber hemoperfusion with the PMX-05R column in elderly patients suffering from septic shock.
Nakamura T; Kawagoe Y; Suzuki T; Shoji H; Ueda Y; Koide H
Am J Med Sci; 2007 Oct; 334(4):244-7. PubMed ID: 18030179
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy.
Berto P; Ronco C; Cruz D; Melotti RM; Antonelli M
Blood Purif; 2011; 32(4):331-40. PubMed ID: 22086346
[TBL] [Abstract][Full Text] [Related]
30. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock.
Mitaka C; Tsuchida N; Kawada K; Nakajima Y; Imai T; Sasaki S
Shock; 2009 Nov; 32(5):478-83. PubMed ID: 19295483
[TBL] [Abstract][Full Text] [Related]
31. The severity of hyperdynamic circulation may predict the effects of direct hemoperfusion with the adsorbent column using polymyxin B-immobilized fiber in patients with gram-negative septic shock.
Uriu K; Osajima A; Kamochi M; Watanabe H; Aibara K; Kaizu K
Ther Apher; 2001 Feb; 5(1):25-30. PubMed ID: 11258606
[TBL] [Abstract][Full Text] [Related]
32. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation.
Shimizu T; Hanasawa K; Sato K; Umeki M; Koga N; Naganuma T; Sato S; Shimonishi T; Ikeda T; Matsuno N; Ono S; Saitoh H; Satoh K; Otani Y; Endo Y; Eguchi Y; Tani T;
Langenbecks Arch Surg; 2009 Mar; 394(2):303-11. PubMed ID: 18685861
[TBL] [Abstract][Full Text] [Related]
33. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES.
Rachoin JS; Foster D; Dellinger RP
Contrib Nephrol; 2010; 167():111-118. PubMed ID: 20519905
[TBL] [Abstract][Full Text] [Related]
34. Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock.
Kase Y; Obata T; Okamoto Y; Iwai K; Saito K; Yokoyama K; Takinami M; Tanifuji Y
Ther Apher Dial; 2008 Oct; 12(5):374-80. PubMed ID: 18937720
[TBL] [Abstract][Full Text] [Related]
35. Exacerbation of prothrombin time-international normalized ratio before second polymyxin B cartridge hemoperfusion predicts poor outcome of patients with severe sepsis and/or septic shock.
Ishizuka M; Terasaki A; Kubota K
J Surg Res; 2016 Jan; 200(1):308-14. PubMed ID: 26319975
[TBL] [Abstract][Full Text] [Related]
36. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study.
Lee WY; Kim HJ; Kim EY
Sci Rep; 2021 Dec; 11(1):24132. PubMed ID: 34916567
[TBL] [Abstract][Full Text] [Related]
37. Polymyxin B hemoperfusion: a mechanistic perspective.
Ronco C; Klein DJ
Crit Care; 2014 Jun; 18(3):309. PubMed ID: 25043934
[TBL] [Abstract][Full Text] [Related]
38. The golden hour of polymyxin B hemoperfusion in endotoxic shock: The basis for sequential extracorporeal therapy in sepsis.
De Rosa S; Villa G; Ronco C
Artif Organs; 2020 Feb; 44(2):184-186. PubMed ID: 31386769
[TBL] [Abstract][Full Text] [Related]
39. Removal of increased circulating CD4+CD25+Foxp3+ regulatory T cells in patients with septic shock using hemoperfusion with polymyxin B-immobilized fibers.
Ono S; Kimura A; Hiraki S; Takahata R; Tsujimoto H; Kinoshita M; Miyazaki H; Yamamoto J; Hase K; Saitoh D
Surgery; 2013 Feb; 153(2):262-71. PubMed ID: 22884251
[TBL] [Abstract][Full Text] [Related]
40. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion.
Novelli G; Ferretti G; Poli L; Pretagostini R; Ruberto F; Perrella SM; Levi Sandri GB; Morabito V; Berloco PB
Transplant Proc; 2010 May; 42(4):1021-4. PubMed ID: 20534214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
